Abstract
Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally thick and sticky mucus. As a consequence following bacterial infections threaten ten thousands of people around the world every year. Available tests enable early diagnosis of CF. Nevertheless, current treatments can only serve to improve patient’s quality of life. Despite the fact that life span of CF patients is dramatically increased with comprehensive treatments during the last decades, there is no ultimate prevention or cure for CF. Chronic respiratory infections are known to be the major cause of morbidity and mortality. Since the airways provide direct access to these bacteria, it is an attractive target for drug delivery against bacterial infections in CF lung. Current pulmonary treatments are, however, limited since reaching the site of action is highly inhibited by the biofilm, which establishes an efficient obstacle for drug diffusion. Recent developments in nanotechnology have led many researchers to study different types of nanoparticles and nanoformulations for pulmonary drug delivery in the scope of providing a solution to current treatment bottlenecks. This review focuses on the development of nanoparticulate antibiotic pulmonary drug delivery systems for the treatment of Pseudomonas aeruginosa infected CF lungs.
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas aeruginosa, pulmonary nanoparticulate drug delivery.
Drug Delivery Letters
Title:Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Volume: 4 Issue: 3
Author(s): Nazende G. Tureli, Akif E. Tureli and Marc Schneider
Affiliation:
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas aeruginosa, pulmonary nanoparticulate drug delivery.
Abstract: Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally thick and sticky mucus. As a consequence following bacterial infections threaten ten thousands of people around the world every year. Available tests enable early diagnosis of CF. Nevertheless, current treatments can only serve to improve patient’s quality of life. Despite the fact that life span of CF patients is dramatically increased with comprehensive treatments during the last decades, there is no ultimate prevention or cure for CF. Chronic respiratory infections are known to be the major cause of morbidity and mortality. Since the airways provide direct access to these bacteria, it is an attractive target for drug delivery against bacterial infections in CF lung. Current pulmonary treatments are, however, limited since reaching the site of action is highly inhibited by the biofilm, which establishes an efficient obstacle for drug diffusion. Recent developments in nanotechnology have led many researchers to study different types of nanoparticles and nanoformulations for pulmonary drug delivery in the scope of providing a solution to current treatment bottlenecks. This review focuses on the development of nanoparticulate antibiotic pulmonary drug delivery systems for the treatment of Pseudomonas aeruginosa infected CF lungs.
Export Options
About this article
Cite this article as:
G. Tureli Nazende, E. Tureli Akif and Schneider Marc, Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review, Drug Delivery Letters 2014; 4 (3) . https://dx.doi.org/10.2174/2210303104666140222002101
DOI https://dx.doi.org/10.2174/2210303104666140222002101 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Modulation of Human Keratinocyte Responses to Solar UV by Plant Polyphenols As a Basis for Chemoprevention of Non-Melanoma Skin Cancers
Current Medicinal Chemistry Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy Evaluation of Anti-cancer Activity of Stilbene and Methoxydibenzo[b,f] oxepin Derivatives
Current Cancer Drug Targets Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways
Anti-Cancer Agents in Medicinal Chemistry Promoter Structure and Transcriptional Regulation of Human β-Galactoside α2, 3-Sialyltransferase Genes
Current Drug Targets Role of Polyamines in Breast Cancer Growth, Development and Progression
Current Cancer Therapy Reviews HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Verbascoside Attenuates Rac-1 and HIF-1α Signaling Cascade in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry